case_images: PMC7450561_01
case_images: Comparison of average SBP and DBP readings in: Case 1. 77 year-old female with multiple myeloma on chemotherapy with bortezomib. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 2. 85 year-old male on ADT with leuprolide and EBRT for prostate cancer. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 3. 79 year-old female on bevacizumab immunotherapy for ovarian carcinosarcoma. Data shows SBP and DBP before and after starting ACEi therapy and after discontinuing it. Case 4. 65 year-old female on chemotherapy with bevacizumab for ovarian cancer. Data shows SBP and DBP DBP before and after starting ACEi therapy and after discontinuing it. Case 5. 72 year-old female on cancer therapy with trastuzumab for breast cancer. Data shows SBP and DBP on and later off ACEi and ARB therapies
case_images: 40959_2020_71_Fig1_HTML.jpg
case_images: PMC7450561_05_40959_2020_71_Fig1_HTML.jpg
case_images: Fig1
case_images: Losartan was later increased to 100 mg daily but BP remained elevated, and even worsened on this regimen (Fig. 1).
case_images: PMC7450561_02
case_images: Comparison of average SBP and DBP readings in: Case 1. 77 year-old female with multiple myeloma on chemotherapy with bortezomib. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 2. 85 year-old male on ADT with leuprolide and EBRT for prostate cancer. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 3. 79 year-old female on bevacizumab immunotherapy for ovarian carcinosarcoma. Data shows SBP and DBP before and after starting ACEi therapy and after discontinuing it. Case 4. 65 year-old female on chemotherapy with bevacizumab for ovarian cancer. Data shows SBP and DBP DBP before and after starting ACEi therapy and after discontinuing it. Case 5. 72 year-old female on cancer therapy with trastuzumab for breast cancer. Data shows SBP and DBP on and later off ACEi and ARB therapies
case_images: 40959_2020_71_Fig1_HTML.jpg
case_images: PMC7450561_05_40959_2020_71_Fig1_HTML.jpg
case_images: Fig1
case_images: Losartan was later increased to 100 mg daily but BP remained elevated, and even worsened on this regimen (Fig. 1).
case_images: PMC7450561_03
case_images: Comparison of average SBP and DBP readings in: Case 1. 77 year-old female with multiple myeloma on chemotherapy with bortezomib. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 2. 85 year-old male on ADT with leuprolide and EBRT for prostate cancer. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 3. 79 year-old female on bevacizumab immunotherapy for ovarian carcinosarcoma. Data shows SBP and DBP before and after starting ACEi therapy and after discontinuing it. Case 4. 65 year-old female on chemotherapy with bevacizumab for ovarian cancer. Data shows SBP and DBP DBP before and after starting ACEi therapy and after discontinuing it. Case 5. 72 year-old female on cancer therapy with trastuzumab for breast cancer. Data shows SBP and DBP on and later off ACEi and ARB therapies
case_images: 40959_2020_71_Fig1_HTML.jpg
case_images: PMC7450561_05_40959_2020_71_Fig1_HTML.jpg
case_images: Fig1
case_images: Losartan was later increased to 100 mg daily but BP remained elevated, and even worsened on this regimen (Fig. 1).
case_images: PMC7450561_04
case_images: Comparison of average SBP and DBP readings in: Case 1. 77 year-old female with multiple myeloma on chemotherapy with bortezomib. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 2. 85 year-old male on ADT with leuprolide and EBRT for prostate cancer. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 3. 79 year-old female on bevacizumab immunotherapy for ovarian carcinosarcoma. Data shows SBP and DBP before and after starting ACEi therapy and after discontinuing it. Case 4. 65 year-old female on chemotherapy with bevacizumab for ovarian cancer. Data shows SBP and DBP DBP before and after starting ACEi therapy and after discontinuing it. Case 5. 72 year-old female on cancer therapy with trastuzumab for breast cancer. Data shows SBP and DBP on and later off ACEi and ARB therapies
case_images: 40959_2020_71_Fig1_HTML.jpg
case_images: PMC7450561_05_40959_2020_71_Fig1_HTML.jpg
case_images: Fig1
case_images: Losartan was later increased to 100 mg daily but BP remained elevated, and even worsened on this regimen (Fig. 1).
case_images: PMC7450561_05
case_images: Comparison of average SBP and DBP readings in: Case 1. 77 year-old female with multiple myeloma on chemotherapy with bortezomib. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 2. 85 year-old male on ADT with leuprolide and EBRT for prostate cancer. Graph shows SBP and DBP on low, high dose, and off ACEi therapy. Case 3. 79 year-old female on bevacizumab immunotherapy for ovarian carcinosarcoma. Data shows SBP and DBP before and after starting ACEi therapy and after discontinuing it. Case 4. 65 year-old female on chemotherapy with bevacizumab for ovarian cancer. Data shows SBP and DBP DBP before and after starting ACEi therapy and after discontinuing it. Case 5. 72 year-old female on cancer therapy with trastuzumab for breast cancer. Data shows SBP and DBP on and later off ACEi and ARB therapies
case_images: 40959_2020_71_Fig1_HTML.jpg
case_images: PMC7450561_05_40959_2020_71_Fig1_HTML.jpg
case_images: Fig1
case_images: Losartan was later increased to 100 mg daily but BP remained elevated, and even worsened on this regimen (Fig. 1).